• CN
    News & Events

    News & Events

    Chipscreen Highlights: Stay Updated on Recent Hot Topics

    Select year

    2026 2025 2024 2023 2022 Earlier
    shown/page
    15
    5 10 15 20

    2021.12.01

    Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
    Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

    Full text

    2021.04.16

    Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)
    Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

    Full text

    2021.01.11

    Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N
    Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N

    Full text

    2020.12.16

    Chipscreen and HISUN reach a strategic cooperation
    Chipscreen and HISUN reach a strategic cooperation

    Full text

    2020.06.24

    Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
    Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

    Full text

    2020.03.24

    Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted
    Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

    Full text

    2019.12.03

    National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
    National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

    Full text

    2019.10.09

    Chipscreen and Novogene enter a strategic partnership for companion diagnostics development
    Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

    Full text

    2019.09.20

    Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted
    Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

    Full text

    2018.05.30

    Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center
    Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center

    Full text

    2018.05.19

    The CHIPSCREEN BIOSCIENCES was invited to participate in celebration of 40th anniversary of WHO Uppsala Monitoring Center
    The CHIPSCREEN BIOSCIENCES was invited to participate in celebration of 40th anniversary of WHO Uppsala Monitoring Center

    Full text

    2018.04.27

    Asian Pharmaceutical Organization Cooperation Conference ( APAC ) and Drug Development Alliance Working Group ( DA-EWG) visits the CHIPSCREEN BIOSCIENCES
    Asian Pharmaceutical Organization Cooperation Conference ( APAC ) and Drug Development Alliance Working Group ( DA-EWG) visits the CHIPSCREEN BIOSCIENCES

    Full text

    2018.04.25

    Master core technology and make China's own innovative medicine - Dr. Lu Xianping, the chairman of CHIPSCREEN BIOSCIENCES, won " 2017 China pharmaceutical development award for outstanding achiev
    Master core technology and make China's own innovative medicine - Dr. Lu Xianping, the chairman of CHIPSCREEN BIOSCIENCES, won " 2017 China pharmaceutical development award for outstanding achiev

    Full text

    2018.04.12

    Dr. Lu was invited to attend the first global forum of 30 Chinese scientists for innovation and transformation
    Dr. Lu was invited to attend the first global forum of 30 Chinese scientists for innovation and transformation

    Full text

    2018.01.03

    Dr. Lu, the president of CHIPSCREEN BIOSCIENCES and the company, were honored with " 2017 Let Love Go Home Project"
    Dr. Lu, the president of CHIPSCREEN BIOSCIENCES and the company, were honored with " 2017 Let Love Go Home Project"

    Full text
    Media contact

    Media contact

    • Media contact

      （+86）0755-36993500

    • Media contact

      pr@juliucq.com